Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
AssigneeAntecip Bioventures II LLC
InventorHerriot Tabuteau
Life of this patent
Estimating the term…
Abstract
This disclosure relates to methods administering various compounds in conjunction with dextromethorphan to a human being. Dosage forms, drug delivery systems, and methods related to dextromethorphan or dextrorphan and bupropion, hydroxybupropion, erythrohydroxybupropion, threohydroxybupropion, or a metabolite or prodrug of any of these compounds are also disclosed.
Claims29
A method of increasing the metabolic lifetime of dextromethorphan, comprising co-administering dextromethorphan with bupropion, hydroxybupropion, erythrohydroxybupropion, or threohydroxybupropion, to a human being who is an extensive metabolizer of dextromethorphan in need of treatment with dextromethorphan, once or twice a day for at least eight consecutive days, wherein bupropion, hydroxybupropion, erythrohydroxybupropion, or threohydroxybupropion is administered in an amount that results in a Cmin of dextromethorphan in the human being, on the eighth day, that is at least about 20 ng/mL and is at least 20 times the Cmin that would have been achieved by administering the same amount of dextromethorphan without bupropion, hydroxybupropion, erythrohydroxybupropion, or threohydroxybupropion for eight consecutive days, and wherein dextromethorphan is present in the body of the human being at the same time as bupropion, hydroxybupropion, erythrohydroxybupropion, or threohydroxybupropion.
A method of increasing the metabolic lifetime of dextromethorphan, comprising co-administering dextromethorphan with bupropion, hydroxybupropion, erythrohydroxybupropion, or threohydroxybupropion, to a human being who is an extensive metabolizer of dextromethorphan in need of treatment with dextromethorphan, once or twice a day for at least eight consecutive days, wherein bupropion, hydroxybupropion, erythrohydroxybupropion, or threohydroxybupropion is administered in an amount that results in an Cmin of dextromethorphan in the human being, on the eighth day, that is at least about 30 ng/mL and is at least 20 times the Cmin that would have been achieved by administering the same amount of dextromethorphan without bupropion, hydroxybupropion, erythrohydroxybupropion, or threohydroxybupropion for eight consecutive days, and wherein dextromethorphan is present in the body of the human being at the same time as bupropion, hydroxybupropion, erythrohydroxybupropion, or threohydroxybupropion.
A method of increasing the metabolic lifetime of dextromethorphan, comprising co-administering dextromethorphan with bupropion, hydroxybupropion, erythrohydroxybupropion, or threohydroxybupropion, to a human being who is an extensive metabolizer of dextromethorphan in need of treatment with dextromethorphan, once or twice a day for at least eight consecutive days, wherein bupropion, hydroxybupropion, erythrohydroxybupropion, or threohydroxybupropion is administered in an amount that results in an Cmin of dextromethorphan in the human being, on the eighth day, that is at least about 40 ng/mL and is at least 30 times the Cmin that would have been achieved by administering the same amount of dextromethorphan without bupropion, hydroxybupropion, erythrohydroxybupropion, or threohydroxybupropion for eight consecutive days, and wherein dextromethorphan is present in the body of the human being at the same time as bupropion, hydroxybupropion, erythrohydroxybupropion, or threohydroxybupropion.
Dependencies are inferred from the claim text.